Literature DB >> 26873858

Molecular Basis of Ligand Dissociation from the Adenosine A2A Receptor.

Dong Guo1, Albert C Pan1, Ron O Dror1, Tamara Mocking1, Rongfang Liu1, Laura H Heitman1, David E Shaw1, Adriaan P IJzerman2.   

Abstract

How drugs dissociate from their targets is largely unknown. We investigated the molecular basis of this process in the adenosine A2Areceptor (A2AR), a prototypical G protein-coupled receptor (GPCR). Through kinetic radioligand binding experiments, we characterized mutant receptors selected based on molecular dynamic simulations of the antagonist ZM241385 dissociating from the A2AR. We discovered mutations that dramatically altered the ligand's dissociation rate despite only marginally influencing its binding affinity, demonstrating that even receptor features with little contribution to affinity may prove critical to the dissociation process. Our results also suggest that ZM241385 follows a multistep dissociation pathway, consecutively interacting with distinct receptor regions, a mechanism that may also be common to many other GPCRs.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26873858     DOI: 10.1124/mol.115.102657

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  29 in total

Review 1.  Protein-ligand (un)binding kinetics as a new paradigm for drug discovery at the crossroad between experiments and modelling.

Authors:  M Bernetti; A Cavalli; L Mollica
Journal:  Medchemcomm       Date:  2017-01-30       Impact factor: 3.597

2.  Photoaffinity Labeling of the Human A2A Adenosine Receptor and Cross-link Position Analysis by Mass Spectrometry.

Authors:  Hideyuki Muranaka; Takaki Momose; Chiaki Handa; Tomonaga Ozawa
Journal:  ACS Med Chem Lett       Date:  2017-05-17       Impact factor: 4.345

3.  Impact of protein-ligand solvation and desolvation on transition state thermodynamic properties of adenosine A2A ligand binding kinetics.

Authors:  Giuseppe Deganutti; Andrei Zhukov; Francesca Deflorian; Stephanie Federico; Giampiero Spalluto; Robert M Cooke; Stefano Moro; Jonathan S Mason; Andrea Bortolato
Journal:  In Silico Pharmacol       Date:  2017-11-20

4.  A binding kinetics study of human adenosine A3 receptor agonists.

Authors:  Lizi Xia; Athina Kyrizaki; Dilip K Tosh; Tirsa T van Duijl; Jacomina Cornelia Roorda; Kenneth A Jacobson; Adriaan P IJzerman; Laura H Heitman
Journal:  Biochem Pharmacol       Date:  2018-01-03       Impact factor: 5.858

Review 5.  Structure-kinetic relationships that control the residence time of drug-target complexes: insights from molecular structure and dynamics.

Authors:  Hao Lu; James N Iuliano; Peter J Tonge
Journal:  Curr Opin Chem Biol       Date:  2018-07-06       Impact factor: 8.822

Review 6.  Perspective: Implications of Ligand-Receptor Binding Kinetics for Therapeutic Targeting of G Protein-Coupled Receptors.

Authors:  Wijnand J C van der Velden; Laura H Heitman; Mette M Rosenkilde
Journal:  ACS Pharmacol Transl Sci       Date:  2020-03-18

Review 7.  Trends in application of advancing computational approaches in GPCR ligand discovery.

Authors:  Siyu Zhu; Meixian Wu; Ziwei Huang; Jing An
Journal:  Exp Biol Med (Maywood)       Date:  2021-02-27

8.  Pathways and Mechanism of Caffeine Binding to Human Adenosine A2A Receptor.

Authors:  Hung N Do; Sana Akhter; Yinglong Miao
Journal:  Front Mol Biosci       Date:  2021-04-27

Review 9.  Gaussian accelerated molecular dynamics for elucidation of drug pathways.

Authors:  Apurba Bhattarai; Yinglong Miao
Journal:  Expert Opin Drug Discov       Date:  2018-10-29       Impact factor: 6.098

10.  Identification of V6.51L as a selectivity hotspot in stereoselective A2B adenosine receptor antagonist recognition.

Authors:  Xuesong Wang; Willem Jespers; Rubén Prieto-Díaz; Maria Majellaro; Adriaan P IJzerman; Gerard J P van Westen; Eddy Sotelo; Laura H Heitman; Hugo Gutiérrez-de-Terán
Journal:  Sci Rep       Date:  2021-07-08       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.